<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04709536</url>
  </required_header>
  <id_info>
    <org_study_id>CIBI306B201</org_study_id>
    <nct_id>NCT04709536</nct_id>
  </id_info>
  <brief_title>A Study of IBI306 in Participants With Hypercholesterolemia</brief_title>
  <official_title>A Randomized, Double-blind, Placebo-controlled Phase III Clinical Study to Evaluate the Efficacy and Safety of IBI306 in Patients With Hypercholesterolemia in China (CREDIT-4)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Innovent Biologics (Suzhou) Co. Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Innovent Biologics (Suzhou) Co. Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is designed for multi-center, double-blind, randomized, placebo-controlled phase&#xD;
      III trial to evaluate the safety and tolerability of subcutaneous injection of IBI306 in&#xD;
      hypercholesterolemia patients.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 9, 2021</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">May 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>1. Mean percent change from baseline in low-density lipoprotein cholesterol (LDL-C) at weeks 12</measure>
    <time_frame>Baseline to week12</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The percent of subjects with LDL-C reduction no less than 50% from baseline</measure>
    <time_frame>Baseline to week24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The percent of subjects with LDL-C&lt;70mg/dL(1.8 mmol/L)</measure>
    <time_frame>Baseline to week24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The percent change in Lp(a),ApoB, non-HDL-c, ApoB/ApoA1 from baseline</measure>
    <time_frame>Baseline to week24</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Hypercholesterolemia</condition>
  <arm_group>
    <arm_group_label>IBI306</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>IBI306 administered subcutaneously (SC)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>administered subcutaneously (SC)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IBI306</intervention_name>
    <description>Recombinant humanized Anti- PCSK9 monoclonal antibody, administered SC from BL to week 24</description>
    <arm_group_label>IBI306</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Recombinant humanized Anti- PCSK9 monoclonal antibody, administered SC from BL to week 24</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria&#xD;
&#xD;
          1. Males and females ≥ 18 to ≤ 75 years of age&#xD;
&#xD;
          2. Diagnosis of hypercholesterolemia&#xD;
&#xD;
          3. LDL cholesterol ≥ 70 mg/dl (1.8mmol/L)&#xD;
&#xD;
          4. Very high or high cardiovascular risk&#xD;
&#xD;
          5. TG≤500 mg/dL(5.64 mmol/L)&#xD;
&#xD;
        Exclusion criteria&#xD;
&#xD;
          1. Uncontrolled hypertension&#xD;
&#xD;
          2. Uncontrolled hyperthyroidism or hypothyroidism&#xD;
&#xD;
          3. Severe renal dysfunction&#xD;
&#xD;
          4. Known sensitivity to any of the products to be administered during dosing&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Yang Yu</last_name>
    <phone>0512-69566088</phone>
    <email>yang.yu@innoventbio.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Peking University First Hospital</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yong Huo</last_name>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>January 12, 2021</study_first_submitted>
  <study_first_submitted_qc>January 12, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 14, 2021</study_first_posted>
  <last_update_submitted>April 29, 2021</last_update_submitted>
  <last_update_submitted_qc>April 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 30, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypercholesterolemia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

